Long-term outcomes for people with immune TTP in the French national TMA cohort

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a retrospective, non-interventional analysis coordinated by the French National Reference Center for Thrombotic Microangiopathies (CNR-MAT) using the national registry. It includes clinical, laboratory (including ADAMTS13 activity and troponin), and treatment data (plasma exchange, immunosuppression, caplacizumab) from over 1,200 patients diagnosed between October 1, 2000 and June 1, 2024. The study links acute-phase features and therapies to long-term outcomes such as major adverse cardiovascular events, cognitive impairment, and survival. Patients with cancer-, HIV-, transplant-associated TTP or severe sepsis are excluded from the cohort, and data reuse follows MR-004 non-interventional rules.

Why it matters

Who can join: the full rules

Inclusion Criteria:

-Patients with a diagnosis of immune mediated TTP

Exclusion Criteria:

* Cancer- associated iTTP and HIV-associated iTTP
* Severe sepsis
* Disseminated intravascular coagulation with consumption of coagulation factors;
* Transplant-associated TTP
* HIV-associated TTP (AIDS stage)
* Patient not affiliated with a social security scheme
* Patient or parent's objection to the reuse of their healthcare data for research

Where it's running

• Service d'Hématologie Hôpital Saint-Antoine
  Paris, France Recruiting

Study contacts

• Principal investigator: Paul COPPO, MD, PHD — Assistance Publique - Hôpitaux de Paris
• Study coordinator: Paul COPPO, MD, PHD
• Email: aul.coppo@aphp.fr
• Phone: 00 33 1 49 28 34 39

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ETHY-001 safety and activity in Thyroid Eye Disease (TED)

  This study tests ETHY-001 versus placebo to see if it is safe, tolerable, and shows activity in people with thyroid eye disease.

  Recruiting at 2 sites Phase 1 Ethyreal Bio, Inc. · Orland Park, Illinois and 2 other locations · NCT07885605

• Abnormal menstrual bleeding in women on antithrombotic drugs after heart surgery

  This study looks at whether women on blood thinners after heart surgery have abnormal menstrual bleeding and what factors might put some at higher risk.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07870941

• AI-powered ECG to help diagnose and predict outcomes in heart disease

  Researchers test an AI-enhanced ECG to help diagnose and predict outcomes for people with cardiovascular diseases.

  Recruiting Inha University Hospital · Incheon, Incheon · NCT07856472

• Colchicine for preventing cardiovascular disease in adults with type 2 diabetes

  A 24-week study will test whether low-dose colchicine can help protect blood vessels in adults with type 2 diabetes who have not yet developed artery disease, compared with a placebo.

  Recruiting Phase 2 Tan Tock Seng Hospital · Singapore, Singapore · NCT07837934

• Optimised Cardio-Renal Care for CKD and heart disease

  This study tests whether a specialised Cardio-Renal Clinic can improve heart and kidney health and quality of life for adults with chronic kidney disease and cardiovascular disease.

  Recruiting Odense University Hospital · Svendborg · NCT07835828

• Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients

  This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.

  Recruiting at 3 sites Phase 3 Pulmovant, Inc. · Kissimmee, Florida and 2 other locations · NCT07816185

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.